Cap 1 Messenger RNA Synthesis with Co-transcriptional CleanCap^® Analog by In Vitro Transcription.

Area of Science:

• Biotechnology
• Molecular Biology
• Synthetic Biology

Background:

• Messenger RNA (mRNA) therapeutics are vital for gene therapy, genome engineering, and vaccine development.
• Effective mRNA requires a 5' cap for gene expression and stability.
• In vitro capping methods include two-step enzymatic reactions or co-transcriptional approaches.

Purpose of the Study:

• To describe and evaluate co-transcriptional capping using TriLink Biotechnology's CleanCap AG for in vitro transcription (IVT).
• To compare the efficiency of co-transcriptional capping with traditional cap analogs.

Main Methods:

• Utilizing CleanCap AG for co-transcriptional capping during the in vitro transcription (IVT) process.
• Performing mRNA purification and analysis following IVT.

Main Results:

• Co-transcriptional capping with CleanCap AG achieved high yields of 5 mg/ml of IVT.
• This method resulted in 94% of the desired 5'-cap 1 structure.
• Demonstrated superior efficiency and yield compared to first-generation cap analogs (mCap, ARCA).

Conclusions:

• Co-transcriptional capping with CleanCap AG is an efficient method for producing high-quality mRNA.
• This approach simplifies mRNA synthesis by minimizing reaction steps and enzyme usage.
• The high efficiency of 5'-cap 1 formation is critical for mRNA therapeutic applications.